Selected research
Industry Research
Brompheniramine Industry Research Report 2026
Market perspective
The global Brompheniramine market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Brompheniramine is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Brompheniramine is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Brompheniramine is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Brompheniramine include AMAG Pharmaceuticals, Endo International, Eon Pharma, Ivax Pharmaceuticals, Newtron Pharmaceuticals, Nexgen Pharma, PAI, Tanta Pharmaceuticals and USL Pharma, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Brompheniramine market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Brompheniramine Market by Company
AMAG Pharmaceuticals
Endo International
Eon Pharma
Ivax Pharmaceuticals
Newtron Pharmaceuticals
Nexgen Pharma
PAI
Tanta Pharmaceuticals
USL Pharma
Watson Laboratories
Pfizer
Merck
Novartis
Teva
Brompheniramine Segment by Type
Oral Solution
Tablet
Brompheniramine Segment by Application
Hospital
Drug Store
Brompheniramine Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Brompheniramine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Brompheniramine and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Brompheniramine.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Brompheniramine manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Brompheniramine by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Brompheniramine in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Oral Solution
- Tablet
Applications
- Hospital
- Drug Store
Companies covered
- AMAG Pharmaceuticals
- Endo International
- Eon Pharma
- Ivax Pharmaceuticals
- Newtron Pharmaceuticals
- Nexgen Pharma
- PAI
- Tanta Pharmaceuticals
- USL Pharma
- Watson Laboratories
- Pfizer
- Merck
- Novartis
- Teva
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Brompheniramine Market Size (2021-2032)
- 2.2.2 Global Brompheniramine Sales (2021-2032)
- 2.2.3 Global Brompheniramine Market Average Price (2021-2032)
- 2.3 Brompheniramine by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Oral Solution
- 2.3.3 Tablet
- 2.4 Brompheniramine by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Hospital
- 2.4.3 Drug Store
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Brompheniramine Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Brompheniramine Sales (K Units) of Manufacturers (2021-2026)
- 3.3 Global Brompheniramine Revenue of Manufacturers (2021-2026)
- 3.4 Global Brompheniramine Average Price by Manufacturers (2021-2026)
- 3.5 Global Brompheniramine Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Brompheniramine, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Brompheniramine, Product Type & Application
- 3.8 Global Manufacturers of Brompheniramine, Established Date
- 3.9 Global Brompheniramine Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 AMAG Pharmaceuticals
- 4.1.1 AMAG Pharmaceuticals Company Information
- 4.1.2 AMAG Pharmaceuticals Business Overview
- 4.1.3 AMAG Pharmaceuticals Brompheniramine Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 AMAG Pharmaceuticals Brompheniramine Product Portfolio
- 4.1.5 AMAG Pharmaceuticals Recent Developments
- 4.2 Endo International
- 4.2.1 Endo International Company Information
- 4.2.2 Endo International Business Overview
- 4.2.3 Endo International Brompheniramine Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Endo International Brompheniramine Product Portfolio
- 4.2.5 Endo International Recent Developments
- 4.3 Eon Pharma
- 4.3.1 Eon Pharma Company Information
- 4.3.2 Eon Pharma Business Overview
- 4.3.3 Eon Pharma Brompheniramine Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Eon Pharma Brompheniramine Product Portfolio
- 4.3.5 Eon Pharma Recent Developments
- 4.4 Ivax Pharmaceuticals
- 4.4.1 Ivax Pharmaceuticals Company Information
- 4.4.2 Ivax Pharmaceuticals Business Overview
- 4.4.3 Ivax Pharmaceuticals Brompheniramine Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Ivax Pharmaceuticals Brompheniramine Product Portfolio
- 4.4.5 Ivax Pharmaceuticals Recent Developments
- 4.5 Newtron Pharmaceuticals
- 4.5.1 Newtron Pharmaceuticals Company Information
- 4.5.2 Newtron Pharmaceuticals Business Overview
- 4.5.3 Newtron Pharmaceuticals Brompheniramine Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Newtron Pharmaceuticals Brompheniramine Product Portfolio
- 4.5.5 Newtron Pharmaceuticals Recent Developments
- 4.6 Nexgen Pharma
- 4.6.1 Nexgen Pharma Company Information
- 4.6.2 Nexgen Pharma Business Overview
- 4.6.3 Nexgen Pharma Brompheniramine Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Nexgen Pharma Brompheniramine Product Portfolio
- 4.6.5 Nexgen Pharma Recent Developments
- 4.7 PAI
- 4.7.1 PAI Company Information
- 4.7.2 PAI Business Overview
- 4.7.3 PAI Brompheniramine Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 PAI Brompheniramine Product Portfolio
- 4.7.5 PAI Recent Developments
- 4.8 Tanta Pharmaceuticals
- 4.8.1 Tanta Pharmaceuticals Company Information
- 4.8.2 Tanta Pharmaceuticals Business Overview
- 4.8.3 Tanta Pharmaceuticals Brompheniramine Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Tanta Pharmaceuticals Brompheniramine Product Portfolio
- 4.8.5 Tanta Pharmaceuticals Recent Developments
- 4.9 USL Pharma
- 4.9.1 USL Pharma Company Information
- 4.9.2 USL Pharma Business Overview
- 4.9.3 USL Pharma Brompheniramine Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 USL Pharma Brompheniramine Product Portfolio
- 4.9.5 USL Pharma Recent Developments
- 4.10 Watson Laboratories
- 4.10.1 Watson Laboratories Company Information
- 4.10.2 Watson Laboratories Business Overview
- 4.10.3 Watson Laboratories Brompheniramine Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Watson Laboratories Brompheniramine Product Portfolio
- 4.10.5 Watson Laboratories Recent Developments
- 4.11 Pfizer
- 4.11.1 Pfizer Company Information
- 4.11.2 Pfizer Business Overview
- 4.11.3 Pfizer Brompheniramine Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 Pfizer Brompheniramine Product Portfolio
- 4.11.5 Pfizer Recent Developments
- 4.12 Merck
- 4.12.1 Merck Company Information
- 4.12.2 Merck Business Overview
- 4.12.3 Merck Brompheniramine Sales, Revenue and Gross Margin (2021-2026)
- 4.12.4 Merck Brompheniramine Product Portfolio
- 4.12.5 Merck Recent Developments
- 4.13 Novartis
- 4.13.1 Novartis Company Information
- 4.13.2 Novartis Business Overview
- 4.13.3 Novartis Brompheniramine Sales, Revenue and Gross Margin (2021-2026)
- 4.13.4 Novartis Brompheniramine Product Portfolio
- 4.13.5 Novartis Recent Developments
- 4.14 Teva
- 4.14.1 Teva Company Information
- 4.14.2 Teva Business Overview
- 4.14.3 Teva Brompheniramine Sales, Revenue and Gross Margin (2021-2026)
- 4.14.4 Teva Brompheniramine Product Portfolio
- 4.14.5 Teva Recent Developments
5 Global Brompheniramine Market Scenario by Region
- 5.1 Global Brompheniramine Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Brompheniramine Sales by Region: 2021-2032
- 5.2.1 Global Brompheniramine Sales by Region: 2021-2026
- 5.2.2 Global Brompheniramine Sales by Region: 2027-2032
- 5.3 Global Brompheniramine Revenue by Region: 2021-2032
- 5.3.1 Global Brompheniramine Revenue by Region: 2021-2026
- 5.3.2 Global Brompheniramine Revenue by Region: 2027-2032
- 5.4 North America Brompheniramine Market Facts & Figures by Country
- 5.4.1 North America Brompheniramine Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Brompheniramine Sales by Country (2021-2032)
- 5.4.3 North America Brompheniramine Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.5 Europe Brompheniramine Market Facts & Figures by Country
- 5.5.1 Europe Brompheniramine Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Brompheniramine Sales by Country (2021-2032)
- 5.5.3 Europe Brompheniramine Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Netherlands
- 5.6 Asia Pacific Brompheniramine Market Facts & Figures by Country
- 5.6.1 Asia Pacific Brompheniramine Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Brompheniramine Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Brompheniramine Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 China Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Brompheniramine Market Facts & Figures by Country
- 5.7.1 South America Brompheniramine Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Brompheniramine Sales by Country (2021-2032)
- 5.7.3 South America Brompheniramine Revenue by Country (2021-2032)
- 5.7.4 Mexico
- 5.7.5 Brazil
- 5.7.6 Argentina
- 5.8 Middle East and Africa Brompheniramine Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Brompheniramine Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Brompheniramine Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Brompheniramine Revenue by Country (2021-2032)
- 5.8.4 Turkey
- 5.8.5 Saudi Arabia
- 5.8.6 UAE
6 Segment by Type
- 6.1 Global Brompheniramine Sales by Type (2021-2032)
- 6.1.1 Global Brompheniramine Sales by Type (2021-2032) & (K Units)
- 6.1.2 Global Brompheniramine Sales Market Share by Type (2021-2032)
- 6.2 Global Brompheniramine Revenue by Type (2021-2032)
- 6.2.1 Global Brompheniramine Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Brompheniramine Revenue Market Share by Type (2021-2032)
- 6.3 Global Brompheniramine Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Brompheniramine Sales by Application (2021-2032)
- 7.1.1 Global Brompheniramine Sales by Application (2021-2032) & (K Units)
- 7.1.2 Global Brompheniramine Sales Market Share by Application (2021-2032)
- 7.2 Global Brompheniramine Revenue by Application (2021-2032)
- 7.2.1 Global Brompheniramine Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Brompheniramine Revenue Market Share by Application (2021-2032)
- 7.3 Global Brompheniramine Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Brompheniramine Value Chain Analysis
- 8.1.1 Brompheniramine Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Brompheniramine Production Mode & Process
- 8.2 Brompheniramine Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Brompheniramine Distributors
- 8.2.3 Brompheniramine Customers
9 Global Brompheniramine Analyzing Market Dynamics
- 9.1 Brompheniramine Industry Trends
- 9.2 Brompheniramine Industry Drivers
- 9.3 Brompheniramine Industry Opportunities and Challenges
- 9.4 Brompheniramine Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst